Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Research article

Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa

Authors: Mweete D Nglazi, Sacha J West, Joel A Dave, Naomi S Levitt, Estelle V Lambert

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

Health related quality of life (HRQoL) is an important outcome helping to understand the impact of antiretroviral therapy (ART). We examined and compared the HRQoL in relation to ART status among HIV-infected patients in a public sector service in Cape Town, South Africa. In addition, we aimed to examine the relationship between ART status and HRQoL according to CD4 count strata.

Methods

A cross sectional study sample of 903 HIV-infected patients who were categorized as not receiving ART (ART-naïve) or receiving first-line ART for > 6 months (ART). HRQoL outcomes were compared in the two groups. HRQoL was assessed using the EQ-5D (five domains) and Visual Analogue Scale (EQ-5D VAS).

Results

Of the total sample, 435 were categorised as ART naïve (76% women) and 468 were on ART (78% women). There were no significant associations between groups for most of the EQ-5D domains, however ART-naïve experienced a significantly greater problem with mobility than the ART group. Being ART-naïve (adjusted odds ratio (aOR) 3.08 95% confidence interval (CI) 1.63- 7.89) and obese 2.78 (95% CI 1.24- 6.22) were identified as predictors for increased mobility problems in multivariate analysis. In addition, receiving ART (5.61 difference; 95% CI 2.50 - 8.72) and having some source of income (4.76; 95% CI 1.63 -7.89) were identified as predictors for a higher EQ-5D VAS score. When grouped according to CD4 count strata, there were no significant difference between groups for most of the EQ-5D domains, however the ART-naïve group indicated having significantly greater problems under the CD4 count of >500 cells/μL in the anxiety/depression domain (22.4% vs 8.8%, p = 0.018) and significantly lower EQ-5D VAS scores under the CD4 counts of ≤200 cells/μL (median 80 (IQR 60–90) vs 90 (IQR 80–100), p = 0.0003) and 201–350 cells/μL (median 80 (IQR 70–90) vs 90 (80–100), p = 0.0004) compared to ART group.

Conclusions

HRQoL (self-rated health state) was improved with ART use, including those with immunocompromised status, which may be relevant to the public sector ART program in South Africa.
Literature
1.
2.
3.
Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. Aids. 2001, 15: 1811-1822. 10.1097/00002030-200109280-00010.CrossRefPubMed
4.
Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWF: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases. 2001, 32: 130-139. 10.1086/317541.CrossRefPubMed
5.
Bradbury RA, Samaras K: Antiretroviral therapy and the human immunodeficiency virus–improved survival but at what cost?. Diabetes Obes Metab. 2008, 10: 441-450. 10.1111/j.1463-1326.2007.00760.x.CrossRefPubMed
6.
Mutimura E, Stewart A, Rheeder P, Crowther NJ: Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007, 46: 451-455. 10.1097/QAI.0b013e318158c0a6.CrossRefPubMedPubMedCentral
7.
Igumbor J, Stewart A, Holzemer W: Comparison of the health-related quality of life, CD4 count and viral load of AIDS patients and people with HIV who have been on treatment for 12 months in rural South Africa. Sahara J. 2013, 10: 25-31.PubMedPubMedCentral
8.
McInerney PA, Ncama BP, Wantland D, Bhengu BR, McGibbon C, Davis SM, Corless IB, Nicholas PK: Quality of life and physical functioning in HIV-infected individuals receiving antiretroviral therapy in KwaZulu-Natal, South Africa. Nurs Health Sci. 2008, 10: 266-272. 10.1111/j.1442-2018.2008.00410.x.CrossRefPubMed
9.
Pitt J, Myer L, Wood R: Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme. J Int AIDS Soc. 2009, 12: 5-10.1186/1758-2652-12-5.CrossRefPubMedPubMedCentral
10.
Louwagie GM, Bachmann MO, Meyer K, Booysen FR, Fairall LR, Heunis C: Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study. BMC Public Health. 2007, 7: 244-10.1186/1471-2458-7-244.CrossRefPubMedPubMedCentral
11.
Jelsma J, Maclean E, Hughes J, Tinise X, Darder M: An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS care. 2005, 17: 579-588. 10.1080/09540120412331319714.CrossRefPubMed
12.
Wouters E, Van Loon F, Van Rensburg D, Meulemans H: State of the ART: clinical efficacy and improved quality of life in the public antiretroviral therapy program, Free State province, South Africa. AIDS Care. 2009, 21: 1401-1411. 10.1080/09540120902884034.CrossRefPubMed
13.
Bhargava A, Booysen Fle R: Healthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South Africa. AIDS Care. 2010, 22: 1-9.CrossRefPubMed
14.
Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007, 45: 34-42. 10.1097/QAI.0b013e318042d5fe.CrossRefPubMed
15.
Domingos H, Cunha RV, Paniago AM, Martins DM, Elkhoury EB, Souza AS: Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis. 2009, 13: 130-136.CrossRefPubMed
16.
van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T: Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010, 104: 148-153. 10.1016/j.trstmh.2009.07.009.CrossRefPubMed
17.
Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT: Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007, 196 (Suppl 3): S449-456.CrossRefPubMed
18.
Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C: Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008, 9: 738-746. 10.1111/j.1468-1293.2008.00616.x.CrossRefPubMed
19.
Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwole-Sida M, Delaporte E, Bork K, Laurent C: Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir Ther. 2010, 15: 1039-1043. 10.3851/IMP1664.CrossRefPubMed
20.
Pedrol E, Martin T, del Pozo MA, Flores J, Sanz J, Carton JA, Jusdado JJ, Arazo P, Ribera E, Deig E: Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions. Med Clin (Barc). 2007, 129: 361-365. 10.1157/13110209.CrossRef
21.
Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Hiransuthikul N, Suankratay C, Kulwichit W: Reduction of D4T Dosage Improves Lipoatrophy Without Virologic Failure. Proceedings of the 2nd IAS Conference on HIV Pathogenesis and Treatment. 2003, Paris, Abstract no.749
22.
Delpierre C, Cuzin L, Alvarez M, Khatibi S, Bonnet E, Obadia M, Massip P: Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients. Proceedings of the 9th European AIDS Conference. 2003, Abstract no.262
23.
Koegl C, Wolf E, Postel N, Buchberger A, Ruemmelein N, Jaegel-Guedes E, Jaeger H: Low Dose Stavudine: As Effective as Standard Dose but Less Side Effects. Proceedings of the 9th European AIDS Conference. 2003, Abstract no.284
24.
Urbina A, Jibilian A, Nibbe Y, Maa JF, Wang S: Long Term Use of Low dose Stavudine is Effective and Well Tolerated. Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005, Abstract no. TuPe2.2B31
25.
Ribera E, Paradiñeiro JC, Domingo P, Sauleda S, Luque S, Garcia-Arumi E, Feijoo M, Fontanet A, Falco V, Crespo M, Ocana I, Sureda D, Planas M, Pahissa A: A Randomized Study Comparing the Efficacy and Tolerability of Lowdose versus Standard-dose Stavudine in Antiretroviral-naïve patients (ETOX Study). Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment. 2005, Abstract no. TuPe2.4 C10
26.
World Health Organization: Antiretroviral therapy for HIV infection in adults and adoloscents. 2010, Geneva: World Health Organization
27.
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama. 2004, 292: 191-201. 10.1001/jama.292.2.191.CrossRefPubMed
28.
29.
Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S: Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr. 2011, 58: e68-74. 10.1097/QAI.0b013e31822a9f8d.CrossRefPubMed
30.
National Department of Health: National Antiretroviral Treatment Guidelines. 2004, Pinetown, South Africa: Jacana Publishers
31.
Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS: Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr. 2011, 57: 284-289. 10.1097/QAI.0b013e318221863f.CrossRefPubMed
32.
Harrison GG, Buskirk ER, Carter JEL, Johnston FE, Lohman TG, Pollock ML, Roche AF, Wilmore J: Skinfold Thicknesses and Measurement Technique. Anthropometric Standardization Reference Manual. Edited by: Lohman TG, Roche AF, Martorel R. 1988, 55-80. 2
33.
Venter E, Gericke GJ, Bekker PJ: Nutritional status, quality of life and CD4 cell count of adults living with HIV/AIDS in the Ga-Rankuwa area (South Africa). S Afr J Clin Nutr. 2009, 22: 124-129.
34.
Durnin JV, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974, 32: 77-97. 10.1079/BJN19740060.CrossRefPubMed
35.
Sampaio LR, Simoes EJ, Assis AM, Ramos LR: Validity and reliability of the sagittal abdominal diameter as a predictor of visceral abdominal fat. Arq Bras Endocrinol Metabol. 2007, 51: 980-986. 10.1590/S0004-27302007000600013.CrossRefPubMed
36.
Badia Llach X, Herdman M, Schiaffino A: Determining correspondence between scores on the EQ-5D “thermometer” and a 5-point categorical rating scale. Med Care. 1999, 37: 671-677. 10.1097/00005650-199907000-00007.CrossRefPubMed
37.
Delate T, Coons SJ: The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001, 32: E47-52. 10.1086/318492.CrossRefPubMed
38.
Gakhar H, Kamali A, Holodniy M: Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs. 2013, 73: 651-672. 10.1007/s40265-013-0040-4.CrossRefPubMedPubMedCentral
39.
40.
National Department of Health: Clinical Guidelines for the Management of HIV&AIDS in Adults and Adolescents. 2010, Pretoria: National Department of Health
41.
Mathews WC, May S: EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes. 2007, 5: 5-10.1186/1477-7525-5-5.CrossRefPubMedPubMedCentral
42.
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST, OPTIMA Team1: Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009, 51: 631-639. 10.1097/QAI.0b013e3181a4f00d.CrossRefPubMed
Metadata
Title
Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa
Authors
Mweete D Nglazi
Sacha J West
Joel A Dave
Naomi S Levitt
Estelle V Lambert
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-676

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue

Research article

Quality of life among people living with hypertension in a rural Vietnam community

Research article

Making progress: the role of cancer councils in Australia in indigenous cancer control

Research article

An update on the prevalence of metabolic syndrome and its associated factors in rural northeast China

Research article

Socioeconomic position and subjective oral health: findings for the adult population in England, Wales and Northern Ireland

Research article

The usefulness of “corrected” body mass index vs. self-reported body mass index: comparing the population distributions, sensitivity, specificity, and predictive utility of three correction equations using Canadian population-based data

Research article

Prevalence and sociodemographic trends of weight misperception in Korean adolescents